Lyu Y, Lin Z H, Yang L, Liu H
Department of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001, China.
Zhonghua Xue Ye Xue Za Zhi. 2024 Mar 14;45(3):290-293. doi: 10.3760/cma.j.cn121090-20230825-00089.
Myelodysplastic syndromes is a heterogeneous group of myeloid neoplastic disorders originating from hematopoietic stem cells and manifesting as pathological bone marrow hematopoiesis and a high risk of transformation to acute myeloid leukemia. In low-risk patients, the therapeutic goal is to improve hematopoiesis and quality of life. Roxadustat is the world's first oral small-molecule hypoxia-inducible factor prolyl hydroxylase inhibitor, which, unlike conventional erythropoietin, corrects anemia through various mechanisms. In this study, we retrospectively analyzed the changes in anemia, iron metabolism, lipids and inflammatory indexes in patients with low-risk myelodysplastic syndromes to evaluate its therapeutic efficacy and safety, and to provide theoretical and practical data for the application of roxadustat in myelodysplastic syndromes.
骨髓增生异常综合征是一组异质性的髓系肿瘤性疾病，起源于造血干细胞，表现为病理性骨髓造血以及转化为急性髓系白血病的高风险。在低危患者中，治疗目标是改善造血功能和生活质量。罗沙司他是全球首个口服小分子低氧诱导因子脯氨酰羟化酶抑制剂，与传统促红细胞生成素不同，它通过多种机制纠正贫血。在本研究中，我们回顾性分析了低危骨髓增生异常综合征患者贫血、铁代谢、血脂及炎症指标的变化，以评估其治疗效果和安全性，并为罗沙司他在骨髓增生异常综合征中的应用提供理论和实践数据。
